ArticleeLife2023
MLL3 regulates the
Open access · goldAbstract read
In one paragraph
Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Histone Methylation and Chromatin Remodeling in Non-Small Cell Lung Cancer: Mechanisms of Oncogenesis and Emerging Therapeutic Strategies.Biomedicines · 2026Review
- Review
- Epigenetic H3K4me3 activation of miR-155-5p promotes intervertebral disc degeneration via autophagy and ageing in nucleus pulposus cells.Non-coding RNA research · 2026Article
- Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships.Nature biomedical engineering · 2026Article
- Molecular mechanisms of KMT2C alterations in gastrointestinal cancers: enhancer network destabilization, lineage plasticity, and clinical translation.Frontiers in immunology · 2026Review
- Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression.Cureus · 2026Review
- KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression.NPJ precision oncology · 2025Article
- Rat Glioma 101.8 Tissue Strain: Molecular and Morphological Features.International journal of molecular sciences · 2025Article
- Review
- Cancer cells' chamber of secrets: the link between micronuclei, chromothripsis and malignancy.Open biology · 2025Review
- LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells.Cell division · 2025Article
- Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.International journal of medical sciences · 2025Review
- Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.Journal of molecular biology · 2024Review
- CDKN2A promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.Molecular biology reports · 2024Article
- The modification role and tumor association with a methyltransferase: KMT2C.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Changyu Zhu *Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0003-3583-3638
Yadira M Soto-Feliciano *Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, United States.ORCID 0000-0002-8523-7917
John P Morris *Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Chun-Hao HuangDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0002-6820-5083
Yu-Jui HoDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Ana BanitoDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0003-2188-0003
Chun-Wei ChenDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0002-8737-6830
Aditya ShroffDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Sha TianDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Geulah LivshitsDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Chi-Chao ChenDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Myles FennellDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.
Scott A ArmstrongDana-Farber Cancer Institute, Boston, United States.ORCID 0000-0002-9099-4728
C David AllisLaboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, United States.
Darjus F TschaharganehHelmholtz-University Group "Cell Plasticity and Epigenetic Remodeling", German Cancer Research Center, Heidelberg, Germany.
Scott W LoweDepartment of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0002-5284-9650
Memorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USGerman Cancer Research Center · DEMassachusetts Institute of Technology · USRockefeller University · USUniversity of North Carolina at Chapel Hill · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVIRAL TRANSACTIVATIONP01CA013106 · NCI · COLD SPRING HARBOR LABORATORY · PI DAVID L SPECTOR · 1985 to 2026
$116.8MRapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignanciesR01CA233944 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W. · 2020 to 2024
$2.4MUnderstanding mechanisms of transcriptional regulation by chromatin adaptor proteinsR00GM140265 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SOTO-FELICIANO, YADIRA M · 2022 to 2024
$747kThe role and regulation of p53 in obesity-induced liver cancerF32CA257103 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZHU, CHANGYU · 2021 to 2023
$210kUnderstanding mechanisms of transcriptional regulation by chromatin adaptor proteinsK99GM140265 · NIGMS · ROCKEFELLER UNIVERSITY · PI SOTO-FELICIANO, YADIRA M · 2021 to 2021
$100kNCI NIH HHS F32 CA257103NCI NIH HHS P01 CA013106NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA233944NIGMS NIH HHS K99 GM140265NIGMS NIH HHS R00 GM140265
Abstract
Mutations in genes encoding components of chromatin modifying and remodeling complexes are among the most frequently observed somatic events in human cancers. For example, missense and nonsense mutations targeting the mixed lineage leukemia family member 3 (MLL3, encoded by
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsAnimalsCarcinogenesisChromatinCyclin-Dependent Kinase Inhibitor p16HumansMiceTumor Suppressor Protein p14ARFCDKN2A protein, humanChromatinCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p14ARFcancercancer biologychromatinhumanliver cancerMLL3mousetumor suppressor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.